Biology and Management of Hop Latent Viroid - Punya Nachappa, PhD Medicinal Genomics 2026-09-21 | Biology and Management of Hop Latent Viroid - Punya Nachappa, PhD
Identifying Fruity & Savory Cannabis Aromas Medicinal Genomics 2024-03-20 | NEW CannMed Coffee Talk, we discuss Analyzing Fruity & Savory Cannabis Aromas! #shorts TJ Martin is the VP of R&D at Abstrax Tech, Inc, a company that specializes in the research, development, and production of botanically derived and cannabis-inspired terpenes. TJ and his team recently published a paper that identified several non-terpenoid compounds that are responsible for the unique aromas associated with exotic cannabis varieties, including the berry, tropical, candy, and fruity notes found in Zkittlez and Gelato as well as the rich, intense, chemical scents found in GMO. This research opens up a new world of aromatic compounds and challenges the idea of classifying cultivars based on terpenes alone. Listen Now: Our conversation covers:⦿ How cannabis aroma affects consumer and patient experience⦿ The variety of aromas the cannabis plant can produce and how it compares to other plants⦿ Define exotic cannabis varieties and compare them to more prototypical cultivars⦿ Why terpenes alone do not tell the entire aroma story in exotic cannabis varieties⦿ How to communicate information about non-terpeninoid compounds to consumers and patients in a meaningful way Thanks to this Episode’s Sponsor: Agilent Technologies
Analyzing Fruity and Savory Cannabis Aromas with TJ Martin Medicinal Genomics 2024-03-20 | TJ Martin is the VP of R&D at Abstrax, a company that specializes in the research, development, and production of botanically derived and cannabis-inspired terpenes. TJ and his team recently published a paper that identified several non-terpenoid compounds that are responsible for the unique aromas associated with exotic cannabis varieties, including the berry, tropical, candy, and fruity notes found in Zkittlez and Gelato as well as the rich, intense, chemical scents found in GMO. This research opens up a new world of aromatic compounds and challenges the idea of classifying cultivars based on terpenes alone. We discuss: - How cannabis aroma affects consumer and patient experience - The variety of aromas the cannabis plant can produce and how it compares to other plants - Define exotic cannabis varieties and compare them to more prototypical cultivars - Why terpenes alone do not tell the entire aroma story in exotic cannabis varieties - How to communicate information about non-terpeninoid compounds to consumers and patients in a meaningful way Thanks to This Episode’s Sponsor: Agilent TechnologiesWhether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly.Learn more at agilent.comAdditional Resources - Minor, Nonterpenoid Volatile Compounds Drive the Aroma Differences of Exotic Cannabis - pubs.acs.org/doi/10.1021/acsomega.3c04496 - Abstraxtech.com [Podcast] Discovering New Aromatic Compounds in Cannabis with TJ Martin - youtu.be/nkPbZvZPFqk - Cannasulfur Compounds: A New Class of Secondary Metabolites Discovered in Cannabis - youtu.be/K8QAwTSMSMY - Cannabis Aroma Predicts User Experience with Adie Rae, PhD - youtu.be/-NBz7UggcFQ - The Nose Knows: Aroma, but Not THC Mediates the Subjective Effects of Smoked and Vaporized Cannabis Flower - mdpi.com/2813-1851/1/2/8 - Register for CannMed 24 - cvent.me/1mGLAq - What Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-unique - Review the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804 - CannMed Archive - cannmedevents.com/cannmed-video-archives
Process for Creating New Cannabis Medicine Combinations - Dustin Sulak, DO Medicinal Genomics 2024-03-14 | Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field.Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 24 this year as one of the medical practicum instructors and an oral presenter, presenting “The Art and Science of Combining Cannabinoids for Treatment Success” We discuss:* What attendees can expect from CannMed Medical Practicum* The expansion of avialble cannabinoids and how Dustin evaluates new options* Which Cannabinoid Dustin would choose if he could only use one to treat patients * The difference between acidic and neutral forms of cannabinoids * The process for combining cannabinoids * Challenging old assumptions about the benefits of combining CBD and THCThanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer’s distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Learn More at healer.comAdditional Resources Healer.com Register for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Uncovering the Differences Between CBD and CBDA - Dustin Sulak, DO Medicinal Genomics 2024-03-12 | Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field.Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 24 this year as one of the medical practicum instructors and an oral presenter, presenting “The Art and Science of Combining Cannabinoids for Treatment Success” We discuss:* What attendees can expect from CannMed Medical Practicum* The expansion of avialble cannabinoids and how Dustin evaluates new options* Which Cannabinoid Dustin would choose if he could only use one to treat patients * The difference between acidic and neutral forms of cannabinoids * The process for combining cannabinoids * Challenging old assumptions about the benefits of combining CBD and THCThanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer’s distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Learn More at healer.comAdditional Resources Healer.com Register for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
The Two Most Impactful Cannabinoids Medicinal Genomics 2024-03-06 | Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field. #shorts Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 24 this year as one of the medical practicum instructors and an oral presenter, presenting “The Art and Science of Combining Cannabinoids for Treatment Success” We discuss:* What attendees can expect from CannMed Medical Practicum* The expansion of available cannabinoids and how Dustin evaluates new options* Which Cannabinoid Dustin would choose if he could only use one to treat patients * The difference between acidic and neutral forms of cannabinoids * The process for combining cannabinoids * Challenging old assumptions about the benefits of combining CBD and THCThanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer’s distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Learn More at healer.com
Combining Cannabinoids for Treatment Success with Dustin Sulak, DO Medicinal Genomics 2024-03-06 | Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field.Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 24 this year as one of the medical practicum instructors and an oral presenter, presenting “The Art and Science of Combining Cannabinoids for Treatment Success” We discuss:* What attendees can expect from CannMed Medical Practicum* The expansion of avialble cannabinoids and how Dustin evaluates new options* Which Cannabinoid Dustin would choose if he could only use one to treat patients * The difference between acidic and neutral forms of cannabinoids * The process for combining cannabinoids * Challenging old assumptions about the benefits of combining CBD and THCThanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer’s distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Learn More at healer.comAdditional Resources Healer.com Register for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
New Cannabinoid Hyperemesis Syndrome (CHS) Study & Observations - Ethan Russo, MD Medicinal Genomics 2024-02-28 | Dr. Ethan Russo is a board-certified neurologist, psychopharmacologist, and Founder/CEO of CReDO Science. He is an internationally recognized authority on cannabis medicine. He has authored/edited seven books and has published more than 60 peer-reviewed articles. He also holds director/advisor positions with several cannabis therapeutics companies, and he was instrumental in developing Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals.At CannMed 24, Ethan will present “Cannabinoid Hyperemesis Syndrome (CHS): Unraveling the Gordian Knot”. CHS is an enigmatic condition where some chronic, heavy users of THC develop a cyclic pattern of vomiting and nausea that is only relieved by hot bathing and topical capsaicin. Ethan and his coinvestigators surveyed more than 500 cannabis users, including 205 diagnosed CHS patients, and investigated genetic mutations in 28 CHS patients and 12 controls to identify behaviors and genetic markers that could indicate CHS risk.During our conversation, we discuss: ⦿ What is CHS and who does it affect ⦿ Why cases of CHS appear to be on the rise ⦿ Possible genetic markers that could indicate CHS susceptibility ⦿ Steps cannabis users can take to prevent developing CHS ⦿ Why some people in the cannabis community don’t believe CHS is a real thing⦿ And more! Thanks to This Episode’s Sponsor: Cannabis Nurses NetworkEstablished in 2015, the Cannabis Nurses Network™ is a professional nursing and professional development organization for nurses around the globe. By educating nurses on the science behind the plant and providing a global nursing network, nurses are supported and empowered to implement their knowledge within their community.Learn more at cannabisnursesnetwork.comAdditional Resourceswhat-is-chs.comethanrusso.orgCReDO-science.comCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - pubmed.ncbi.nlm.nih.gov/34227878Unraveling the Mystery of Cannabinoid Hyperemesis Syndrome – youtu.be/X-8im4X9HXM?si=lVWLPge3oRHD6o0vCannMed 2019 PanelRegister for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
What is Cannabinoid Hyperemesis Syndrome (CHS)? - Ethan Russo, MD Medicinal Genomics 2024-02-26 | Dr. Ethan Russo is a board-certified neurologist, psychopharmacologist, and Founder/CEO of CReDO Science. He is an internationally recognized authority on cannabis medicine. He has authored/edited seven books and has published more than 60 peer-reviewed articles. He also holds director/advisor positions with several cannabis therapeutics companies, and he was instrumental in developing Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals.At CannMed 24, Ethan will present “Cannabinoid Hyperemesis Syndrome (CHS): Unraveling the Gordian Knot”. CHS is an enigmatic condition where some chronic, heavy users of THC develop a cyclic pattern of vomiting and nausea that is only relieved by hot bathing and topical capsaicin. Ethan and his coinvestigators surveyed more than 500 cannabis users, including 205 diagnosed CHS patients, and investigated genetic mutations in 28 CHS patients and 12 controls to identify behaviors and genetic markers that could indicate CHS risk.During our conversation, we discuss: ⦿ What is CHS and who does it affect ⦿ Why cases of CHS appear to be on the rise ⦿ Possible genetic markers that could indicate CHS susceptibility ⦿ Steps cannabis users can take to prevent developing CHS ⦿ Why some people in the cannabis community don’t believe CHS is a real thing⦿ And more! Thanks to This Episode’s Sponsor: Cannabis Nurses NetworkEstablished in 2015, the Cannabis Nurses Network™ is a professional nursing and professional development organization for nurses around the globe. By educating nurses on the science behind the plant and providing a global nursing network, nurses are supported and empowered to implement their knowledge within their community.Learn more at cannabisnursesnetwork.comAdditional Resourceswhat-is-chs.comethanrusso.orgCReDO-science.comCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - pubmed.ncbi.nlm.nih.gov/34227878Unraveling the Mystery of Cannabinoid Hyperemesis Syndrome – youtu.be/X-8im4X9HXM?si=lVWLPge3oRHD6o0vCannMed 2019 PanelRegister for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Largest Cannabinoid Hyperemesis Syndrome (CHS) Study Medicinal Genomics 2024-02-21 | NEW CannMed Coffee Talk, we discuss Unraveling Cannabinoid Hyperemesis Syndrome! #shorts Listen Now: youtu.be/4h-NYwdfGTEDr. Ethan Russo is a board-certified neurologist, psychopharmacologist, and Founder/CEO of CReDO Science LLC. He is an internationally recognized authority on cannabis medicine. He has authored/edited seven books and has published more than 60 peer-reviewed articles. He also holds director/advisor positions with several cannabis therapeutics companies, and he was instrumental in developing Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals.At CannMed 24, Ethan will present “Cannabinoid Hyperemesis Syndrome (CHS): Unraveling the Gordian Knot”. View Here: cannmedevents.com/ethan-russo-mdOur conversation covers:⦿ What is CHS and who does it affect ⦿ Why cases of CHS appear to be on the rise ⦿ Possible genetic markers that could indicate CHS susceptibility ⦿ Steps cannabis users can take to prevent developing CHS ⦿ Why some people in the cannabis community don’t believe CHS is a real thing⦿ And more! Thanks to this Episode’s Sponsor: @cannanursesnetwork
Unraveling Cannabinoid Hyperemesis Syndrome with Ethan Russo, MD Medicinal Genomics 2024-02-21 | Dr. Ethan Russo is a board-certified neurologist, psychopharmacologist, and Founder/CEO of CReDO Science. He is an internationally recognized authority on cannabis medicine. He has authored/edited seven books and has published more than 60 peer-reviewed articles. He also holds director/advisor positions with several cannabis therapeutics companies, and he was instrumental in developing Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals.At CannMed 24, Ethan will present “Cannabinoid Hyperemesis Syndrome (CHS): Unraveling the Gordian Knot”. CHS is an enigmatic condition where some chronic, heavy users of THC develop a cyclic pattern of vomiting and nausea that is only relieved by hot bathing and topical capsaicin. Ethan and his coinvestigators surveyed more than 500 cannabis users, including 205 diagnosed CHS patients, and investigated genetic mutations in 28 CHS patients and 12 controls to identify behaviors and genetic markers that could indicate CHS risk.During our conversation, we discuss: What is CHS and who does it affect Why cases of CHS appear to be on the rise Possible genetic markers that could indicate CHS susceptibility Steps cannabis users can take to prevent developing CHS Why some people in the cannabis community don’t believe CHS is a real thingand more Thanks to This Episode’s Sponsor: Cannabis Nurses NetworkEstablished in 2015, the Cannabis Nurses Network™ is a professional nursing and professional development organization for nurses around the globe. By educating nurses on the science behind the plant and providing a global nursing network, nurses are supported and empowered to implement their knowledge within their community.Learn more at cannabisnursesnetwork.comAdditional Resourceswhat-is-chs.comethanrusso.orgCReDO-science.comCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - pubmed.ncbi.nlm.nih.gov/34227878Unraveling the Mystery of Cannabinoid Hyperemesis Syndrome – youtu.be/X-8im4X9HXM?si=lVWLPge3oRHD6o0vCannMed 2019 PanelRegister for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Deciding What Conditions to Investigate & The Process of Evaluation - Akeem Gardner, LLB Medicinal Genomics 2024-02-14 | Akeem Gardner is the Founder and CEO of Canurta. He is an innovative entrepreneur with over five years of experience in industrial hemp enterprises. He has a proven track record in leading high-performance teams that work across multi-channel platforms and strategically aligning profitability with sustainability and economic development in Ontario. At CannMed 24 Akeem will present Effect of Cannflavins on Mitigating a Motor Neuron Disease. During our conversation we discuss: ⦿ The minor molecules found in cannabis that Canurta is investigating for therapeutics⦿ Canurta’s process for evaluating indications for cannflavins and polyphenols ⦿ How the diverse molecules in cannabis make it a great therapeutic for multifactoral diseases like ALS ⦿ The potential for cannflavins and polyphenols may be used as a anti-inflammatory nutraceutical ⦿ and more!Thanks to This Episode's Sponsor: American Cannabis Nurses AssociationACNA is a national nursing organization whose mission is to advance excellence in cannabis nursing practice through advocacy, collaboration, education, research, and policy development. Founded in 2010, ACNA continues to work on providing its members with up-to-date cannabis information and resources to care for patients who use cannabis. Join them today at cannabisnurses.org and be a part of the change.Additional Resources Akeem on LinkedIn - linkedin.com/in/akeemgardnerEmail Akeem at Akeem@Canurta.comCanurta Journal Page - canurta.com/journalRegister for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Medicine Application for ALS / Motor Neuron Disease - Akeem Gardner, LLB Medicinal Genomics 2024-02-12 | Akeem Gardner is the Founder and CEO of Canurta. He is an innovative entrepreneur with over five years of experience in industrial hemp enterprises. He has a proven track record in leading high-performance teams that work across multi-channel platforms and strategically aligning profitability with sustainability and economic development in Ontario. At CannMed 24 Akeem will present Effect of Cannflavins on Mitigating a Motor Neuron Disease. During our conversation we discuss: ⦿ The minor molecules found in cannabis that Canurta is investigating for therapeutics⦿ Canurta’s process for evaluating indications for cannflavins and polyphenols ⦿ How the diverse molecules in cannabis make it a great therapeutic for multifactoral diseases like ALS ⦿ The potential for cannflavins and polyphenols may be used as a anti-inflammatory nutraceutical ⦿ and more!Thanks to This Episode's Sponsor: American Cannabis Nurses AssociationACNA is a national nursing organization whose mission is to advance excellence in cannabis nursing practice through advocacy, collaboration, education, research, and policy development. Founded in 2010, ACNA continues to work on providing its members with up-to-date cannabis information and resources to care for patients who use cannabis. Join them today at cannabisnurses.org and be a part of the change.Additional Resources Akeem on LinkedIn - linkedin.com/in/akeemgardnerEmail Akeem at Akeem@Canurta.comCanurta Journal Page - canurta.com/journalRegister for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Using Minor Molecules in The Cannabis Plant - Akeem Gardner, LLB Medicinal Genomics 2024-02-07 | NEW CannMed Coffee Talk, we discuss Using Cannflavins to Mitigate Motor Neuron Disease!Akeem Gardner is the Founder and CEO of Canurta. He is an innovative entrepreneur with over five years of experience in industrial hemp enterprises. He has a proven track record in leading high-performance teams that work across multi-channel platforms and strategically aligning profitability with sustainability and economic development in Ontario.At CannMed 24 Akeem will present "Effect of Cannflavins on Mitigating a Motor Neuron Disease." View Here: cannmedevents.com/akeem-gardnerOur conversation covers:⦿ The minor molecules found in cannabis that Canurta is investigating for therapeutics⦿ Canurta’s process for evaluating indications for cannflavins and polyphenols⦿ How the diverse molecules in cannabis make it a great therapeutic for multifactoral diseases like ALS⦿ The potential for cannflavins and polyphenols may be used as a anti-inflammatory nutraceutical⦿ and more!Thanks to this Episode’s Sponsor: American Cannabis Nurses Association (ACNA)
Using Cannflavins to Mitigate Motor Neuron Disease with Akeem Gardner Medicinal Genomics 2024-02-07 | Akeem Gardner is the Founder and CEO of Canurta. He is an innovative entrepreneur with over five years of experience in industrial hemp enterprises. He has a proven track record in leading high-performance teams that work across multi-channel platforms and strategically aligning profitability with sustainability and economic development in Ontario. At CannMed 24 Akeem will present Effect of Cannflavins on Mitigating a Motor Neuron Disease. During our conversation we discuss: * The minor molecules found in cannabis that Canurta is investigating for therapeutics* Canurta’s process for evaluating indications for cannflavins and polyphenols * How the diverse molecules in cannabis make it a great therapeutic for multifactoral diseases like ALS * The potential for cannflavins and polyphenols may be used as a anti-inflammatory nutraceutical * and moreThanks to This Episode's Sponsor: American Cannabis Nurses AssociationACNA is a national nursing organization whose mission is to advance excellence in cannabis nursing practice through advocacy, collaboration, education, research, and policy development. Founded in 2010, ACNA continues to work on providing its members with up-to-date cannabis information and resources to care for patients who use cannabis. Join them today at cannabisnurses.org and be a part of the change.Additional Resources Akeem on LinkedIn - linkedin.com/in/akeemgardnerEmail Akeem at Akeem@Canurta.comCanurta Journal Page - canurta.com/journalRegister for CannMed 24 - cvent.me/1mGLAqWhat Makes CannMed Unique and Why You Don’t Want to Miss It - medicinalgenomics.com/what-makes-cannmed-uniqueReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Evaluating Endotoxin Levels on Cannabis Flower Medicinal Genomics 2024-01-24 | Kevin McKernan is the Chief Scientific Officer and Founder of Medicinal Genomics. Kevin has pioneered the genomics of cannabis and hemp to build a stronger scientific environment for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. At CannMed 24 he will present “Understanding the Prevalence and Risks Associated with Endotoxins on Cannabis Flower”, which will include novel research he did to measure the level of endotoxins in store-bought cannabis flower. Our conversation covers: * What inspired Kevin to look into endotoxin levels on cannabis * Which microbes produce endotoxins * How endotoxins affect humans * Whether remediation techniques mask endotoxin risks * and moreThanks to This Episode's Sponsor: Agilent Technologies
Evaluating Endotoxin Levels on Cannabis Flower with Kevin McKernan Medicinal Genomics 2024-01-24 | Kevin McKernan is the Chief Scientific Officer and Founder of Medicinal Genomics. Kevin has pioneered the genomics of cannabis and hemp to build a stronger scientific environment for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. At CannMed 24 he will present “Understanding the Prevalence and Risks Associated with Endotoxins on Cannabis Flower”, which will include novel research he did to measure the level of endotoxins in store-bought cannabis flower. Our conversation covers: * What inspired Kevin to look into endotoxin levels on cannabis * Which microbes produce endotoxins * How endotoxins affect humans * Whether remediation techniques mask endotoxin risks * and moreThanks to This Episode's Sponsor: Agilent Technologies. Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly.Learn more at agilent.comAdditional Resources High levels of endotoxins in commercial cannabis flower [Pre-Print] - osf.io/preprints/osf/gdqbxTotal Yeast and Mold - A Comparison Study - Jini Glaros [CannMed 23 Presentation] - youtu.be/Q8Aa1x0L0yM Register for CannMed 24 - cvent.me/1mGLAqReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Capital Markets Workshop: An Overview & Who Should Attend - David Traylor Medicinal Genomics 2024-01-17 | David Traylor is Senior Managing Director at Golden Eagle Partners, and organizer of the CannMed 24 Capital Markets Workshop.After advising on various transactions in the life science sector, David took an interest in the cannabis sector and started advising cannabis companies before eventually re-founding Golden Eagle Partners in 2014 to focus on advising companies across the cannabis sector. Before Golden Eagle Partners, David served at leading investment banking firms including Pacific Growth Equities, Caris & Company, and Headwaters MB. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling over $500 million in value.David and Golden Eagle Partners will host a Capital Markets Workshop at CannMed 24 which will explore a global perspective of the hurdles, issues, and concepts around funding cannabinoid and cannabis innovation. During our conversation we discuss:⦿ What attendees can expect from the Capital Markets Workshop⦿ Redefining the cannabis nomenclature⦿ The likelihood the DEA will reschedule cannabis this year⦿ Pharma’s growing interest in cannabis-derived compounds⦿ Challenges cannabis innovators face when raising capitalThanks to This Episode’s Sponsor: Golden Eagle PartnersLearn more at: goldeneaglepartners.com
Cannabis Rescheduling: From Schedule I to Schedule III - David Traylor Medicinal Genomics 2024-01-15 | David Traylor is Senior Managing Director at Golden Eagle Partners, and organizer of the CannMed 24 Capital Markets Workshop.After advising on various transactions in the life science sector, David took an interest in the cannabis sector and started advising cannabis companies before eventually re-founding Golden Eagle Partners in 2014 to focus on advising companies across the cannabis sector. Before Golden Eagle Partners, David served at leading investment banking firms including Pacific Growth Equities, Caris & Company, and Headwaters MB. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling over $500 million in value.David and Golden Eagle Partners will host a Capital Markets Workshop at CannMed 24 which will explore a global perspective of the hurdles, issues, and concepts around funding cannabinoid and cannabis innovation. During our conversation we discuss:⦿ What attendees can expect from the Capital Markets Workshop⦿ Redefining the cannabis nomenclature⦿ The likelihood the DEA will reschedule cannabis this year⦿ Pharma’s growing interest in cannabis-derived compounds⦿ Challenges cannabis innovators face when raising capitalThanks to This Episode’s Sponsor: Golden Eagle PartnersLearn more at: goldeneaglepartners.com
Funding Innovation in Cannabis Medicinal Genomics 2024-01-10 | David Traylor is Senior Managing Director at Golden Eagle Partners, and organizer of the CannMed 24 Capital Markets Workshop. #shorts Learn More about the Capital Markets Workshop: cannmedevents.com/capital-markets-workshopAfter advising on various transactions in the life science sector, David took an interest in the cannabis sector and started advising cannabis companies before eventually re-founding Golden Eagle Partners in 2014 to focus on advising companies across the cannabis sector. Before Golden Eagle Partners, David served at leading investment banking firms including Pacific Growth Equities, Caris & Company, and Headwaters MB. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling over $500 million in value.David and Golden Eagle Partners will host a Capital Markets Workshop at CannMed 24 which will explore a global perspective of the hurdles, issues, and concepts around funding cannabinoid and cannabis innovation. During our conversation we discuss:⦿ What attendees can expect from the Capital Markets Workshop⦿ Redefining the cannabis nomenclature⦿ The likelihood the DEA will reschedule cannabis this year⦿ Pharma’s growing interest in cannabis-derived compounds⦿ Challenges cannabis innovators face when raising capitalThanks to This Episode’s Sponsor: Golden Eagle PartnersLearn more at: goldeneaglepartners.com
Funding Innovation in Cannabis with David Traylor Medicinal Genomics 2024-01-10 | David Traylor is Senior Managing Director at Golden Eagle Partners, and organizer of the CannMed 24 Capital Markets Workshop.After advising on various transactions in the life science sector, David took an interest in the cannabis sector and started advising cannabis companies before eventually re-founding Golden Eagle Partners in 2014 to focus on advising companies across the cannabis sector. Before Golden Eagle Partners, David served at leading investment banking firms including Pacific Growth Equities, Caris & Company, and Headwaters MB. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling over $500 million in value.David and Golden Eagle Partners will host a Capital Markets Workshop at CannMed 24 which will explore a global perspective of the hurdles, issues, and concepts around funding cannabinoid and cannabis innovation. During our conversation we discuss:What attendees can expect from the Capital Markets WorkshopRedefining the cannabis nomenclatureThe likelihood the DEA will reschuelde cannabis this yearPharma’s growing interest in cannabis-derived compoundsChallenges cannabis innovators face when raising capitalThanks to This Episode’s Sponsor: Golden Eagle PartnersGolden Eagle Partners are transactional experts, specializing in mergers, acquisitions, reverse mergers, financings and incremental transactions such as licensing, joint ventures and co-development arrangements. Their combined experience in the early stages of the cannabis and life science sectors allows them to confidently close strategic and financing transactions that match the near- and long-term goals of their clients.Learn more at goldeneaglepartners.com Additional ResourcesReclassifying Cannabis: What The HHS Recommendation Means For The Cannabis Market [Benzinga Podcast] - youtube.com/live/yMLGNp3qLyA?si=IlEMGCG6QeRnNDv8David Traylor on LinkedIn - linkedin.com/in/david-w-traylorRegister for CannMed 24 - cvent.me/1mGLAqReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Keeping Up with Cannabinoid Medicine Research with Bonni Goldstein, MD Medicinal Genomics 2023-12-27 | Dr. Bonni Goldstein is one of the country’s most respected and experienced medical cannabis physicians, having treated thousands of patients with medical cannabis. She is the owner and medical director of Canna-Centers Wellness & Education. She is Clinical Advisor to Cannformatics. And she is the author of the book titled “Cannabis is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain”. Bonni Goldstein is one of the country’s most respected and experienced medical cannabis physicians, having treated thousands of patients with medical cannabis. She is the owner and medical director of Canna-Centers Wellness & Education. She is Clinical Advisor to Cannformatics, and she is the author of the book titled “Cannabis is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain”. Bonni has participated in every CannMed event since we started in 2016, she is a perennial Advisory Board Member, and she will lead the CannMed Medical practicum again in 2024. During our conversation we talked about: What attendees can expect from CannMed Medical PracticumNew research that she is excited about concerning THCA and CBDA Her method for customizing cannabinoid formulations for her patients The many barriers preventing patients from using cannabis How the cannabinoid medicine options have expanded over the last decade The difficulty of keeping up with the cannabis medicine literature Thanks to This Episode’s Sponsor: The DENT InstituteWith more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson’s, Dementia, Neuro-Oncology, etc. With our mission of advancing neuroscience, we established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout our institute.Learn more at dentinstitute.comAdditional ResourcesCannabis is Medicine by Bonni Goldstein, MD [Book] - amazon.com/Cannabis-Medicine-Medical-Healing-Everything/dp/031650078X@bonnigoldsteinmd on Instagram - instagram.com/bonnigoldsteinmdBonni Goldstein, MD on LinkedIn - linkedin.com/in/bonnigoldsteinmdReview the Podcast! - podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804CannMed Archive - cannmedevents.com/cannmed-video-archives
Cannabis Impairment Test Types - Patricia DiCiano, PhD Medicinal Genomics 2023-12-20 | Dr. Patricia DiCiano is a scientist with the Institute for Mental Health and Policy Research at the Centre for Addiction and Mental Health (CAMH). She is also an assistant professor in the Department of Pharmacology and Toxicology at the University of Toronto. Patricia has a multi-disciplinary background and her general research area is clinical trials and regulated studies into the safety of cannabis and other substances of abuse. Earlier this year, she co-authored a study that evaluated the utility of THC cutoff levels in blood and saliva for the detection of impaired driving. During our conversation, we discussed: The different allowable limits for THC levels in drivers The relationship between THC levels and impaired driving The best fluid to test for THC impairment The additive effects of combining alcohol and cannabis on driving impairment The differences in how alcohol and cannabis affect driving performance Thanks to this episode’s sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more. Learn more at trustedcannanurse.com Additional Resources- The Utility of THC Cutoff Levels in Blood and Saliva for Detection of Impaired Driving - liebertpub.com/doi/full/10.1089/can.2022.0187- Canadian Cannabis Survey - canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data.html- The “Next Day” Effects of Cannabis Use: A Systematic Review - liebertpub.com/doi/10.1089/can.2022.0185- Register for CannMed 24 - web.cvent.com/event/ab5a72c8-0b7f-48d0-90e4-e7b4aa71f639/regPage:7b1d74cb-5a31-4ee4-8d74-0f42f411f3fa?rp=45d139f5-cb9c-4122-84a9-65456109bf02- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives
Canada Cannabis Driving Limits - Patricia DiCiano, PhD Medicinal Genomics 2023-12-18 | Dr. Patricia DiCiano is a scientist with the Institute for Mental Health and Policy Research at the Centre for Addiction and Mental Health (CAMH). She is also an assistant professor in the Department of Pharmacology and Toxicology at the University of Toronto. Patricia has a multi-disciplinary background and her general research area is clinical trials and regulated studies into the safety of cannabis and other substances of abuse. Earlier this year, she co-authored a study that evaluated the utility of THC cutoff levels in blood and saliva for the detection of impaired driving. During our conversation, we discussed: The different allowable limits for THC levels in drivers The relationship between THC levels and impaired driving The best fluid to test for THC impairment The additive effects of combining alcohol and cannabis on driving impairment The differences in how alcohol and cannabis affect driving performance Thanks to this episode’s sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more. Learn more at trustedcannanurse.com Additional Resources- The Utility of THC Cutoff Levels in Blood and Saliva for Detection of Impaired Driving - liebertpub.com/doi/full/10.1089/can.2022.0187- Canadian Cannabis Survey - canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data.html- The “Next Day” Effects of Cannabis Use: A Systematic Review - liebertpub.com/doi/10.1089/can.2022.0185- Register for CannMed 24 - web.cvent.com/event/ab5a72c8-0b7f-48d0-90e4-e7b4aa71f639/regPage:7b1d74cb-5a31-4ee4-8d74-0f42f411f3fa?rp=45d139f5-cb9c-4122-84a9-65456109bf02- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives
Evaluating THC Cutoff Levels for Impaired Driving Medicinal Genomics 2023-12-13 | Dr. Patricia DiCiano is a scientist with the Institute for Mental Health and Policy Research at the Centre for Addiction and Mental Health (CAMH). She is also an assistant professor in the Department of Pharmacology and Toxicology at the University of Toronto. Patricia has a multi-disciplinary background and her general research area is clinical trials and regulated studies into the safety of cannabis and other substances of abuse. Earlier this year, she co-authored a study that evaluated the utility of THC cutoff levels in blood and saliva for the detection of impaired driving. During our conversation, we discussed: The different allowable limits for THC levels in drivers The relationship between THC levels and impaired driving The best fluid to test for THC impairment The additive effects of combining alcohol and cannabis on driving impairment The differences in how alcohol and cannabis affect driving performance Thanks to this episode’s sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more. Learn more at trustedcannanurse.com #shorts Additional Resources- The Utility of THC Cutoff Levels in Blood and Saliva for Detection of Impaired Driving - liebertpub.com/doi/full/10.1089/can.2022.0187- Canadian Cannabis Survey - canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data.html- The “Next Day” Effects of Cannabis Use: A Systematic Review - liebertpub.com/doi/10.1089/can.2022.0185- Register for CannMed 24 - web.cvent.com/event/ab5a72c8-0b7f-48d0-90e4-e7b4aa71f639/regPage:7b1d74cb-5a31-4ee4-8d74-0f42f411f3fa?rp=45d139f5-cb9c-4122-84a9-65456109bf02- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives
Evaluating THC Cutoff Levels for Impaired Driving with Patricia DiCiano, PhD Medicinal Genomics 2023-12-13 | Dr. Patricia DiCiano is a scientist with the Institute for Mental Health and Policy Research at the Centre for Addiction and Mental Health (CAMH). She is also an assistant professor in the Department of Pharmacology and Toxicology at the University of Toronto. Patricia has a multi-disciplinary background and her general research area is clinical trials and regulated studies into the safety of cannabis and other substances of abuse. Earlier this year, she co-authored a study that evaluated the utility of THC cutoff levels in blood and saliva for the detection of impaired driving. During our conversation, we discussed: The different allowable limits for THC levels in drivers The relationship between THC levels and impaired driving The best fluid to test for THC impairment The additive effects of combining alcohol and cannabis on driving impairment The differences in how alcohol and cannabis affect driving performance Thanks to this episode’s sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more. Learn more at trustedcannanurse.com Additional Resources- The Utility of THC Cutoff Levels in Blood and Saliva for Detection of Impaired Driving - liebertpub.com/doi/full/10.1089/can.2022.0187- Canadian Cannabis Survey - canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data.html- The “Next Day” Effects of Cannabis Use: A Systematic Review - liebertpub.com/doi/10.1089/can.2022.0185- Register for CannMed 24 - web.cvent.com/event/ab5a72c8-0b7f-48d0-90e4-e7b4aa71f639/regPage:7b1d74cb-5a31-4ee4-8d74-0f42f411f3fa?rp=45d139f5-cb9c-4122-84a9-65456109bf02- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives
Critical Weed Free Period in Hemp - Karla Gage, PhD Medicinal Genomics 2023-12-07 | On this week’s CannMed Coffee Talk, we discuss Weed Control and Outdoor Hemp!Dr. Karla Gage is Assistant Professor of Weed Science and Plant Biology at Southern Illinois University Carbondale, where she received her Ph.D. in Plant Biology with a focus in Weed Ecology in 2013. In short, Karla is a weed expert, but not in the weed you smoke, but rather the weeds you pull. Her research focuses on using Integrated Weed Management to control and suppress weeds in midwestern US rotational crops, including corn, soybean, wheat, sorghum, and now hemp. During our conversation we discussed: ⦾ What negative effects weeds can have on hemp ⦾ Which weed species are threatening to hemp ⦾ Herbicides that are approved for hemp and the threat of herbicide resistance ⦾ Integrated weed management strategies, such as, crop rotation, cover crops, and chaff lining, plastic coverings, and more ⦾ How ferral hemp varieties may have traits to help breed more resistant hemp varieties.Thanks to this Episode’s Sponsor: Rare Earth GenomicsRare Earth Genomics Texas is a partnership formed to accelerate hemp research and produce critical tools for the farmer. REG’s mission is to increase likelihood of a successful harvest through genetic analysis and rigorous environmental testing of vigorous cultivars. Reliable datasets, analytic tools and stable germplasm are core to the program. Success of the farmer is the goal!
Regional Considerations For Weed Control and Growing Hemp - Karla Gage, PhD Medicinal Genomics 2023-12-05 | On this week’s CannMed Coffee Talk, we discuss Weed Control and Outdoor Hemp!Dr. Karla Gage is Assistant Professor of Weed Science and Plant Biology at Southern Illinois University Carbondale, where she received her Ph.D. in Plant Biology with a focus in Weed Ecology in 2013. In short, Karla is a weed expert, but not in the weed you smoke, but rather the weeds you pull. Her research focuses on using Integrated Weed Management to control and suppress weeds in midwestern US rotational crops, including corn, soybean, wheat, sorghum, and now hemp. During our conversation we discussed: ⦾ What negative effects weeds can have on hemp ⦾ Which weed species are threatening to hemp ⦾ Herbicides that are approved for hemp and the threat of herbicide resistance ⦾ Integrated weed management strategies, such as, crop rotation, cover crops, and chaff lining, plastic coverings, and more ⦾ How ferral hemp varieties may have traits to help breed more resistant hemp varieties.Thanks to this Episode’s Sponsor: Rare Earth GenomicsRare Earth Genomics Texas is a partnership formed to accelerate hemp research and produce critical tools for the farmer. REG’s mission is to increase likelihood of a successful harvest through genetic analysis and rigorous environmental testing of vigorous cultivars. Reliable datasets, analytic tools and stable germplasm are core to the program. Success of the farmer is the goal!
Hop Latent Viroid Infection and Tissue Culture - Bill Graham Medicinal Genomics 2023-12-02 | Bill Graham is the Founder of Microclone Tissue Culture, a company that provides tissue culture kits, consulting, and training to cannabis cultivators.With hands-on expertise, he retailed and distributed hydroponics supplies, sourced grow lights globally, created Biojuice nutrients, designed Phresh filter air quality systems, and simplified micropropagation cloning – creating the leading microclone tissue culture kits in 2005.During our conversation, we discussed:- The basics of tissue culture- Tissue culture as propagation alternative to cloning- How mother plants can lead to pathogen infections and loss of vigor- Combining tissue culture and qPCR to eliminate pathogens, such as hop latent viroid- and more!Additional Resources- microclone.com- Microclone on YouTube -youtube.com/playlist?list=PL3889D2A0445E5B4A- Register for CannMed 24 -cvent.me/1mGLAq- Submit an Abstract for CannMed 24 - cvent.com/c/abstracts/ec356f22-1e98-4c0f-a46c-0fb1d4d9ade8- Review the Podcast! -podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
Cannabis Impairment Biomarkers | Danielle McCartney, PhD Medicinal Genomics 2023-12-02 | Dr. Danielle McCartney is a Postdoctoral Research Associate at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, where her main role is to coordinate clinical research into the effects of cannabidiol on simulated car driving performance. Danielle and her colleagues recently published a systematic review of 20 studies that examine the next-day effects of THC. As the study states, “The length of time an individual should wait following cannabis use before performing safety-sensitive tasks, is a critical issue.” Some government agencies and experts recommend individuals avoid performing safety-sensitive tasks for at least 24 hours. It should not surprise you to learn that the data suggests a much shorter impairment window.During our conversation, we discuss: - The different types of studies the authors reviewed and the criteria they used to evaluate them - The different tests administered to measure impairment- How next-day effects of THC compare to acute effects - How next-day effects are different in medicinal cannabis patients vs recreational users - What methods are available to determine THC impairment in drivers- What is a reasonable impairment window for THC Additional Resources- The “Next Day” Effects of Cannabis Use: A Systematic Review - liebertpub.com/doi/10.1089/can.2022.0185- Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review - sciencedirect.com/science/article/pii/S0149763421000178?via%3Dihub#!- Lambert Initiative for Cannabinoid Therapeutics - https://www.sydney.edu.au/lambert/- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
Is Rescheduling Cannabis A Step in The Right Direction? - Laszlo Mechtler, MD Medicinal Genomics 2023-12-01 | Dr. Laszlo Mechtler is the Chief Medical Officer at the DENT Neurologic Institute, the largest outpatient neuroscience center in the United States. Dr. Mechtler is the Director of the DENT Cannabis Clinic, which has more than 15,000 patients certified through the NYS MMJ program and continues to grow each day. He has published some of the first major retrospective research trials on Medical Marijuana in Headaches and other neurologic disorders and lectures both nationally and internationally and is recognized as a leader in the fields of Neuroimaging, Headache Medicine, Neuro-Oncology, and Medical Cannabis. Dr. Mechtler is also a member for he CannMed 24 Advisory Board. During our conversation we discuss: - How the DENT Institute is uniquely positioned to study medical cannabis for a variety of conditions - Results from recent studies conducted at the DENT Cannabis Clinic - The challenges of studying cannabis medicine and how a proposed rescheduling could help - The ongoing struggle to convince fellow clinicians and medical associations that medical cannabis is legitimate Thanks to This Episode's Sponsor: The DENT InstituteWith more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson’s, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute.
How Did the Dent Institute Get Involved in Cannabis? Laszlo Mechtler, MD Medicinal Genomics 2023-11-30 | Dr. Laszlo Mechtler is the Chief Medical Officer at the DENT Neurologic Institute, the largest outpatient neuroscience center in the United States. Dr. Mechtler is the Director of the DENT Cannabis Clinic, which has more than 15,000 patients certified through the NYS MMJ program and continues to grow each day. He has published some of the first major retrospective research trials on Medical Marijuana in Headaches and other neurologic disorders and lectures both nationally and internationally and is recognized as a leader in the fields of Neuroimaging, Headache Medicine, Neuro-Oncology, and Medical Cannabis. Dr. Mechtler is also a member for he CannMed 24 Advisory Board. During our conversation we discuss: - How the DENT Institute is uniquely positioned to study medical cannabis for a variety of conditions - Results from recent studies conducted at the DENT Cannabis Clinic - The challenges of studying cannabis medicine and how a proposed rescheduling could help - The ongoing struggle to convince fellow clinicians and medical associations that medical cannabis is legitimate Thanks to This Episode's Sponsor: The DENT InstituteWith more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson’s, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute.
Weed Control and Growing Hemp - Karla Gage, PhD Medicinal Genomics 2023-11-29 | On this week’s CannMed Coffee Talk, we discuss Weed Control and Outdoor Hemp!Dr. Karla Gage is Assistant Professor of Weed Science and Plant Biology at Southern Illinois University Carbondale, where she received her Ph.D. in Plant Biology with a focus in Weed Ecology in 2013. In short, Karla is a weed expert, but not in the weed you smoke, but rather the weeds you pull. Her research focuses on using Integrated Weed Management to control and suppress weeds in midwestern US rotational crops, including corn, soybean, wheat, sorghum, and now hemp. During our conversation we discussed: ⦾ What negative effects weeds can have on hemp ⦾ Which weed species are threatening to hemp ⦾ Herbicides that are approved for hemp and the threat of herbicide resistance ⦾ Integrated weed management strategies, such as, crop rotation, cover crops, and chaff lining, plastic coverings, and more ⦾ How ferral hemp varieties may have traits to help breed more resistant hemp varieties #shorts Thanks to this Episode’s Sponsor: Rare Earth Genomics
Weed Control and Outdoor Hemp - Karla Gage, PhD Medicinal Genomics 2023-11-29 | On this week’s CannMed Coffee Talk, we discuss Weed Control and Outdoor Hemp!Dr. Karla Gage is Assistant Professor of Weed Science and Plant Biology at Southern Illinois University Carbondale, where she received her Ph.D. in Plant Biology with a focus in Weed Ecology in 2013. In short, Karla is a weed expert, but not in the weed you smoke, but rather the weeds you pull. Her research focuses on using Integrated Weed Management to control and suppress weeds in midwestern US rotational crops, including corn, soybean, wheat, sorghum, and now hemp. During our conversation we discussed: ⦾ What negative effects weeds can have on hemp ⦾ Which weed species are threatening to hemp ⦾ Herbicides that are approved for hemp and the threat of herbicide resistance ⦾ Integrated weed management strategies, such as, crop rotation, cover crops, and chaff lining, plastic coverings, and more ⦾ How ferral hemp varieties may have traits to help breed more resistant hemp varieties.Thanks to this Episode’s Sponsor: Rare Earth GenomicsRare Earth Genomics Texas is a partnership formed to accelerate hemp research and produce critical tools for the farmer. REG’s mission is to increase likelihood of a successful harvest through genetic analysis and rigorous environmental testing of vigorous cultivars. Reliable datasets, analytic tools and stable germplasm are core to the program. Success of the farmer is the goal!
What is Tissue Culture? - Bill Graham Medicinal Genomics 2023-11-16 | Bill Graham is the Founder of Microclone Tissue Culture, a company that provides tissue culture kits, consulting, and training to cannabis cultivators.With hands-on expertise, he retailed and distributed hydroponics supplies, sourced grow lights globally, created Biojuice nutrients, designed Phresh filter air quality systems, and simplified micropropagation cloning – creating the leading microclone tissue culture kits in 2005.During our conversation, we discussed:- The basics of tissue culture- Tissue culture as propagation alternative to cloning- How mother plants can lead to pathogen infections and loss of vigor- Combining tissue culture and qPCR to eliminate pathogens, such as hop latent viroid- and more!Additional Resources- microclone.com- Microclone on YouTube -youtube.com/playlist?list=PL3889D2A0445E5B4A- Register for CannMed 24 -cvent.me/1mGLAq- Submit an Abstract for CannMed 24 - cvent.com/c/abstracts/ec356f22-1e98-4c0f-a46c-0fb1d4d9ade8- Review the Podcast! -podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
Legitimizing Cannabis Medicine with Laszlo Mechtler, MD Medicinal Genomics 2023-11-15 | Dr. Laszlo Mechtler is the Chief Medical Officer at the DENT Neurologic Institute, the largest outpatient neuroscience center in the United States. Dr. Mechtler is the Director of the DENT Cannabis Clinic, which has more than 15,000 patients certified through the NYS MMJ program and continues to grow each day. He has published some of the first major retrospective research trials on Medical Marijuana in Headaches and other neurologic disorders and lectures both nationally and internationally and is recognized as a leader in the fields of Neuroimaging, Headache Medicine, Neuro-Oncology, and Medical Cannabis. Dr. Mechtler is also a member for he CannMed 24 Advisory Board. During our conversation we discuss: - How the DENT Institute is uniquely positioned to study medical cannabis for a variety of conditions - Results from recent studies conducted at the DENT Cannabis Clinic - The challenges of studying cannabis medicine and how a proposed rescheduling could help - The ongoing struggle to convince fellow clinicians and medical associations that medical cannabis is legitimate Thanks to This Episode's Sponsor: The DENT InstituteWith more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson’s, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute.
What is Tissue Culture? Medicinal Genomics 2023-11-01 | On this week’s CannMed Coffee Talk, we discuss Using Tissue Culture to Accelerate Propagation and Combat Pathogens! #shorts Bill Graham is the Founder of Microclone Tissue Culture, a company that provides tissue culture kits, consulting, and training to cannabis cultivators. With hands-on expertise, he retailed and distributed hydroponics supplies, sourced grow lights globally, created Biojuice nutrients, designed Phresh filter air quality systems, and simplified micropropagation cloning – creating the leading Microclone tissue culture kits in 2005.Watch Now: youtube.com/watch?v=z18fxL7US-wDuring our conversation, we discussed:⦿ The basics of tissue culture⦿ Tissue culture as propagation alternative to cloning⦿ How mother plants can lead to pathogen infections and loss of vigor⦿ Combining tissue culture and qPCR to eliminate pathogens, such as hop latent viroid⦿ And more!Thanks to this Episode’s Sponsor: Cambium Analytica
Using Tissue Culture to Accelerate Propagation and Combat Pathogens Medicinal Genomics 2023-11-01 | Bill Graham is the Founder of Microcline Tissue Culture, a company that provides tissue culture kits, consulting, and training to cannabis cultivators. With hands-on expertise, he retailed and distributed hydroponics supplies, sourced grow lights globally, created Biojuice nutrients, designed Phresh filter air quality systems, and simplified micropropagation cloning - creating the leading Microclone tissue culture kits in 2005. During our conversation we discussed: * The basics of tissue culture * Tissue culture as propagation alternative to cloning * How mother plants can lead to pathogen infections and loss of vigor * Combining tissue culture and qPCR to eliminate pathogens, such as hop latent viroid * and more! Thanks to This Episode's Sponsor: Cambium AnalyticaCambium Analytica, provides analytical, product development, and quality assurance services for the natural foods, botanical products, natural pharmaceutical, and dietary supplement industries. Cambium is a leading research organization that is focused on leveraging its expertise on drug discovery and method development, to be a research partner of choice for new innovative companies in the burgeoning botanical medicines space. Their focus on applying analytical techniques in combination with sensory, product development, and consumer research is driving advancement in natural product quality and innovation. Learn more at cambiumanalytica.com Additional Resources- microclone.com- Microclone on YouTube - youtube.com/playlist?list=PL3889D2A0445E5B4A- Register for CannMed 24 - web.cvent.com/event/ab5a72c8-0b7f-48d0-90e4-e7b4aa71f639/regPage:7b1d74cb-5a31-4ee4-8d74-0f42f411f3fa?rp=45d139f5-cb9c-4122-84a9-65456109bf02 - Submit an Abstract for CannMed 24 - cvent.com/c/abstracts/ec356f22-1e98-4c0f-a46c-0fb1d4d9ade8- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
Pathogenic Aspergillus & Cannabis Medicinal Genomics 2023-10-19 | On this week’s CannMed Coffee Talk, we discuss The Risk of Pathogenic Aspergillus and Cannabis! #shorts David W. Denning is a Professor of Infectious Diseases in Global Health at The University of Manchester in the United Kingdom. He was the founding president, executive director, and CEO of Global Action For Fungal Infections, an organization dedicated to reducing the worldwide burden of fungal disease.In 2016, he became the director of the National Aspergillosis Centre in Manchester, which treats patients with chronic pulmonary aspergillosis (CPA), and led the committee that developed the first CPA guidelines. He chairs the editorial board of a website which focuses on aspergillus and he leads an organization which provides education on fungal diseases. During our conversation, we discuss:◎ Should cannabis be tested for pathogenic Aspergillus◎ Should there be an allowable limit for pathogenic Aspergillus?◎ Is Aspergillosis only a concern for immunocompromised patients? ◎ Are the number of Aspergillosis cases under reported? ◎ How difficult is Aspergillosis to diagnose and treat? ◎ How ubiquitous is Aspergillus in the air we breathe? ◎ And so much more!
The Risk of Pathogenic Aspergillus in Cannabis with David Denning Medicinal Genomics 2023-10-18 | David W. Denning is a Professor of Infectious Diseases in Global Health at the University of Manchester in the United Kingdom. He was the founding president, executive director, and CEO of Global Action For Fungal Infections, an organization dedicated to reducing the worldwide burden of fungal disease.In 2016, he became the director of the National Aspergillosis Centre in Manchester, which treats patients with chronic pulmonary aspergillosis (CPA), and led the committee that developed the first CPA guidelines. He chairs the editorial board of a website that focusses on Aspergillus and he leads an organization that provides education on fungal diseases. In short, Dr. Denning is the leading authority on all things Aspergillus, and we asked him many of the questions that have been debated on social media recently, including: * Should cannabis be tested for pathogenic Aspergillus* Should there be an allowable limit for pathogenic Aspergillus?* Is Apergillosis only a concern for immunocompromised patients? * Are the number of Aspergillosis cases under reported? * How difficult is Aspergillosis to diagnose and treat? * How ubiquitous is Aspergillus in the air we breathe? * and so much more.
Networking & Collaboration - CannMed 24 | May 12-15, 2024 | Marco Island, FL Medicinal Genomics 2023-10-06 | By learning from and networking with other industry leaders, you can return from the summit with the information and the connections you need to take your business to the next level. Allow us to introduce you to the CannMed 24 Innovation and Investment Summit, an exclusive experience of discovery, development, and networking with innovators from around the world. Since 2016, CannMed has regularly featured some of the greatest minds in medicinal plant medicine, cultivation, and safety testing. It is the most sought-after forum in which to announce the latest research and technologies while networking with current and prospective customers.In this supercharged environment, CannMed 24 gathers stakeholders from across the industry, along with leaders from financial institutions who come together to forge enduring partnerships.Learn more at cannmedevents.com
Cannabinoid Concentration and Temperature Medicinal Genomics 2023-10-05 | Mitchell Westmoreland is a Ph.D. candidate working with Dr. Bruce Bugbee in the Crop Physiology Laboratory at Utah State University. His Ph.D. research focuses on whole-plant physiology and cultivation of medical Cannabis in controlled environments. He has published his research on photobiology and plant nutrition in high-impact peer-reviewed scientific journals.I spoke with Mitch about the various environmental factors that contribute to cannabis yield, specifically light, temperature, humidity, and CO2. Mitch does a great job explaining the energy cascade, which describes the underlying mechanisms that plants use to convert photons to energy and ultimately biomass. Mitch also explains how those factors can be manipulated to not only increase yield but also make better use of resources.
Manipulating Environmental Factors to Improve Cannabis Yield with Mitchell Westmoreland Medicinal Genomics 2023-10-04 | Mitchell Westmoreland is a Ph.D. candidate working with Dr. Bruce Bugbee in the Crop Physiology Laboratory at Utah State University. His Ph.D. research focuses on whole-plant physiology and cultivation of medical Cannabis in controlled environments. He has published his research on photobiology and plant nutrition in high-impact peer-reviewed scientific journals. I spoke with Mitch about the various environmental factors that contribute to cannabis yield, specifically light, temperature, humidity, and CO2. Mitch does a great job explaining the energy cascade, which describes the underlying mechanisms that plants use to convert photons to energy and ultimately biomass. Mitch also explains how those factors can be manipulated to not only increase yield but also make better use of resources. I really enjoyed the conversation, and I expect we will see Mitchell on the CannMed stage very soon. Thanks to This Episode's Sponsor: Advanced Nutrients. Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community, and continues to revolutionize the space through proprietary scientific discoveries. Learn more at advancednutrients.com Additional Resources- Elevated UV photon fluxes minimally affected cannabinoid concentration in a high-CBD cultivar - frontiersin.org/articles/10.3389/fpls.2023.1220585/full- Cannabis lighting: Decreasing blue photon fraction increases yield but efficacy is more important for cost effective production of cannabinoids - journals.plos.org/plosone/article?id=10.1371/journal.pone.0248988- Sustainable Cannabis Nutrition: Elevated root-zone phosphorus significantly increases leachate P and does not improve yield or quality - frontiersin.org/articles/10.3389/fpls.2022.1015652/full- An approach to crop modeling with the energy cascade - researchgate.net/publication/11807032_An_approach_to_crop_modeling_with_the_energy_cascade?enrichId=rgreq-934adf2d7faf4322de75c8f47fe3da66-XXX&enrichSource=Y292ZXJQYWdlOzExODA3MDMyO0FTOjIyMjE5NDExMTEyNzU1MkAxNDI5OTg2NjEyMjc4&el=1_x_3&_esc=publicationCoverPdf- Exploring the Limits of Crop Productivity - ncbi.nlm.nih.gov/pmc/articles/PMC1055676/pdf/plntphys00633-0369.pdf- The Science and Technology of Medical Cannabis Cultivation Utah State University Couse - https://caas.usu.edu/labs/cpl/cannabis/online-course- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
Getting to Know Cannabigerol (CBG) Medicinal Genomics 2023-09-28 | Dr. Bonni Goldstein is one of the country’s most respected and experienced medical cannabis physicians, having treated thousands of patients with medical cannabis. She is the owner and medical director of Canna-Centers Wellness & Education. She is Clinical Advisor to Cannformatics. And she is the author of the book titled “Cannabis is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain” #shorts During our conversation, we discuss:◎ What makes CBG one of Bonni’s favorite new cannabinoids◎ What makes CBG a “bridge” cannabinoid between THC and CBD◎ The difference between CBGA and CBG◎ How CBG enhances the body’s natural endocannabinoid system◎ How CBG works in combination with other cannabinoids◎ Conditions for which CBG is a good fit◎ Potential adverse reactions to CBG◎ A preview of the CannMed Medical Practicum
Are There Next Day Effects of THC? - Danielle McCartney, PhD Medicinal Genomics 2023-09-28 | Dr. Danielle McCartney is a Postdoctoral Research Associate at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, where her main role is to coordinate clinical research into the effects of cannabidiol on simulated car driving performance. Danielle and her colleagues recently published a systematic review of 20 studies that examine the next-day effects of THC. As the study states, “The length of time an individual should wait following cannabis use before performing safety-sensitive tasks, is a critical issue.” Some government agencies and experts recommend individuals avoid performing safety-sensitive tasks for at least 24 hours. It should not surprise you to learn that the data suggests a much shorter impairment window.During our conversation, we discuss: - The different types of studies the authors reviewed and the criteria they used to evaluate them - The different tests administered to measure impairment- How next-day effects of THC compare to acute effects - How next-day effects are different in medicinal cannabis patients vs recreational users - What methods are available to determine THC impairment in drivers- What is a reasonable impairment window for THC Additional Resources- The “Next Day” Effects of Cannabis Use: A Systematic Review - liebertpub.com/doi/10.1089/can.2022.0185- Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review - sciencedirect.com/science/article/pii/S0149763421000178?via%3Dihub#!- Lambert Initiative for Cannabinoid Therapeutics - https://www.sydney.edu.au/lambert/- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
World’s Largest Phenotype Hunt Medicinal Genomics 2023-09-26 | On this week's CannMed Coffee Talk we welcome Nathaniel Pennington, Founder and CEO of Humboldt Seed Company. #shorts Nat and his team have been supplying high-quality cannabis seeds to growers since 2001. In 2018 they hosted the World’s Largest Phenotype Hunt, teaming with local farmers, industry experts, and top researchers. We talked about the Mega Phenotype Project as well as Nat’s process for breeding consistent and reproducible cannabis seeds. Topics include:- The Phenotype Rating Sheet used to evaluate plants- The process of creating stable, pure-bred lines- Why Humboldt Seed Company chooses to sell pure-bred lines- Benefits of growing from seed rather than clone- Benefits of autoflower varieties and common misconceptions- The importance of legacy growers collaborating with academics and researchers
Reviewing Next Day Effects of THC with Danielle McCartney, PhD Medicinal Genomics 2023-09-20 | Dr. Danielle McCartney is a Postdoctoral Research Associate at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, where her main role is to coordinate clinical research into the effects of cannabidiol on simulated car driving performance. Danielle and her colleagues recently published a systematic review of 20 studies that examine the next-day effects of THC. As the study states, “The length of time an individual should wait following cannabis use before performing safety-sensitive tasks, is a critical issue.” Some government agencies and experts recommend individuals avoid performing safety-sensitive tasks for at least 24 hours. It should not surprise you to learn that the data suggests a much shorter impairment window.During our conversation, we discuss: - The different types of studies the authors reviewed and the criteria they used to evaluate them - The different tests administered to measure impairment- How next-day effects of THC compare to acute effects - How next-day effects are different in medicinal cannabis patients vs recreational users - What methods are available to determine THC impairment in drivers- What is a reasonable impairment window for THC Additional Resources- The “Next Day” Effects of Cannabis Use: A Systematic Review - liebertpub.com/doi/10.1089/can.2022.0185- Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review - sciencedirect.com/science/article/pii/S0149763421000178?via%3Dihub#!- Lambert Initiative for Cannabinoid Therapeutics - https://www.sydney.edu.au/lambert/- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
Location & Venue - CannMed 24 | May 12-15, 2024 | Marco Island, FL Medicinal Genomics 2023-09-19 | Immerse yourself in the sophisticated luxury of the JW Marriott Marco Island Beach Resort. With three miles of white sandy beaches on the Gulf of Mexico, this newly renovated resort balances relaxation with elevated fun and entertainment. Sample cuisine from around the globe at the resort's 12 restaurants. Tee off from one of two championship golf courses, take a yoga class, network with colleagues, or simply unwind by the pool. This exquisite hotel spa offers luxury services and massages to help you recharge and rejuvenate, while you reconnect with our CannMed community.Allow us to introduce you to the CannMed 24 Innovation and Investment Summit, an exclusive experience of discovery, development, and networking with innovators from around the world. Since 2016, CannMed has regularly featured some of the greatest minds in medicinal plant medicine, cultivation, and safety testing. It is the most sought-after forum in which to announce the latest research and technologies while networking with current and prospective customers.In this supercharged environment, CannMed 24 gathers stakeholders from across the industry, along with leaders from financial institutions who come together to forge enduring partnerships.Learn more at cannmedevents.com
How Post Harvest Activities Affect TYM Levels - Zamir Punja, PhD Medicinal Genomics 2023-08-15 | Zamir Punja, PhD is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases on vegetable and horticultural crops, and the applications of plant biotechnology for disease management. Since 2018, his work has shifted to researching cannabis, where his group has described a range of previously unreported pathogens affecting the crop and has evaluated various methods for disease management. His team just published the results of a 3-year study that identified several factors related to growing, drying, and trimming cannabis that have a direct affect on Yeast and Mold levels. This is important because when growers fail for microbial testing, yeast and mold is most often the reason. So if you are a grower who has struggled with total yeast and mold, perhaps these findings can help you get back on track. I’ve put a link to the paper in the show description, and if you are watching on YouTube, I have added several figures and images from the paper throughout the conversation. Thanks to This Episode's Sponsor: Agilent Technologies.Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly.Learn more at agilent.comAdditional Resources- Total yeast and mold levels in high THC-containing cannabis (Cannabis sativa L.) inflorescences are influenced by genotype, environment, and pre-and post-harvest handling practices- frontiersin.org/articles/10.3389/fmicb.2023.1192035/full- 5 Factors Causing Cannabis to Fail Total Yeast and Mold - medicinalgenomics.com/5-factors-causing-cannabis-to-fail-total-yeast-and-mold- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
Relationship of Genotype and TYM Levels - Zamir Punja, PhD Medicinal Genomics 2023-08-08 | Zamir Punja, PhD is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases on vegetable and horticultural crops, and the applications of plant biotechnology for disease management. Since 2018, his work has shifted to researching cannabis, where his group has described a range of previously unreported pathogens affecting the crop and has evaluated various methods for disease management. His team just published the results of a 3-year study that identified several factors related to growing, drying, and trimming cannabis that have a direct affect on Yeast and Mold levels. This is important because when growers fail for microbial testing, yeast and mold is most often the reason. So if you are a grower who has struggled with total yeast and mold, perhaps these findings can help you get back on track. I’ve put a link to the paper in the show description, and if you are watching on YouTube, I have added several figures and images from the paper throughout the conversation. Thanks to This Episode's Sponsor: Agilent Technologies.Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly.Learn more at agilent.comAdditional Resources- Total yeast and mold levels in high THC-containing cannabis (Cannabis sativa L.) inflorescences are influenced by genotype, environment, and pre-and post-harvest handling practices- frontiersin.org/articles/10.3389/fmicb.2023.1192035/full- 5 Factors Causing Cannabis to Fail Total Yeast and Mold - medicinalgenomics.com/5-factors-causing-cannabis-to-fail-total-yeast-and-mold- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
Managing Total Yeast and Mold with Zamir Punja, PhD Medicinal Genomics 2023-08-02 | Zamir Punja, PhD is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases on vegetable and horticultural crops, and the applications of plant biotechnology for disease management. Since 2018, his work has shifted to researching cannabis, where his group has described a range of previously unreported pathogens affecting the crop and has evaluated various methods for disease management. His team just published the results of a 3-year study that identified several factors related to growing, drying, and trimming cannabis that have a direct affect on Yeast and Mold levels. This is important because when growers fail for microbial testing, yeast and mold is most often the reason. So if you are a grower who has struggled with total yeast and mold, perhaps these findings can help you get back on track. I’ve put a link to the paper in the show description, and if you are watching on YouTube, I have added several figures and images from the paper throughout the conversation. We covered: * The different species of yeast and mold that are commonly found on cannabis and which are potentially harmful to humans * The value of TYM testing as an indicator of product safety and quality * What is a reasonable threshold for Total Yeast and Mold* How Cannabis genotype affects TYM levels * Why leaf litter drives up TYM levels * Why hang drying is a better method than wet trimming * The drawbacks of irradiation * And more Thanks to This Episode's Sponsor: Agilent Technologies.Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly.Learn more at agilent.comAdditional Resources- Total yeast and mold levels in high THC-containing cannabis (Cannabis sativa L.) inflorescences are influenced by genotype, environment, and pre-and post-harvest handling practices- frontiersin.org/articles/10.3389/fmicb.2023.1192035/full- 5 Factors Causing Cannabis to Fail Total Yeast and Mold - medicinalgenomics.com/5-factors-causing-cannabis-to-fail-total-yeast-and-mold- Review the Podcast! - podcasts.apple.com/tt/podcast/cannmed-coffee-talk/id1504218804- CannMed Archive - cannmedevents.com/cannmed-video-archives- CannMed Community Board [Facebook Group] - facebook.com/groups/cannmedcommunity
